| NCT06865105 | AbbVie | Psoriatic Arthritis | 2025-04-11 | PHASE2 |
| NCT07071519 | AbbVie | Ulcerative Colitis | 2025-07-28 | PHASE3 |
| NCT03478787 | AbbVie | Psoriasis | 2018-05-08 | PHASE3 |
| NCT06346288 | AbbVie | Inflammatory Bowel Disease | 2024-04-24 | PHASE4 |
| NCT04583956 | National Institute of Allergy and Infectious Diseases (NIAID) | COVID-19 | 2020-10-23 | PHASE2 |
| NCT04846959 | AbbVie|PPD Development, LP | Plaque Psoriasis, Psoriatic Arthritis, Crohn´s Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment | 2021-07-30 | |
| NCT05274087 | AbbVie | Healthy Volunteers | 2020-09-15 | PHASE1 |
| NCT05305222 | AbbVie | Healthy Volunteers | 2017-10-23 | PHASE1 |
| NCT02772601 | AbbVie|Boehringer Ingelheim | Psoriasis | 2016-09-15 | PHASE1 |
| NCT06298188 | Shaare Zedek Medical Center | Crohn Disease | 2024-10-31 | NA |
| NCT03219437 | AbbVie | Psoriasis | 2018-07-30 | PHASE3 |
| NCT02684357 | AbbVie|Boehringer Ingelheim | Psoriasis | 2016-03 | PHASE3 |
| NCT05283681 | AbbVie | Healthy Volunteers | 2019-04-02 | PHASE1 |
| NCT04862286 | AbbVie | Psoriasis | 2021-07-24 | PHASE3 |
| NCT06548542 | AbbVie | Crohn´s Disease | 2024-09-04 | PHASE2 |
| NCT05567029 | AbbVie | Healthy Volunteers | 2022-09-28 | PHASE1 |
| NCT05928039 | University of Calgary|Alimentiv Inc. | Crohn Disease | 2023-10-25 | PHASE4 |
| NCT06063967 | AbbVie | Crohn´s Disease | 2023-11-15 | PHASE3 |
| NCT06249555 | Alimentiv Inc.|Takeda | Crohn´s Disease | 2024-03-20 | |
| NCT03671148 | AbbVie | Psoriatic Arthritis (PsA) | 2019-03-07 | PHASE3 |
| NCT06487572 | AbbVie | Healthy Volunteers | 2024-07-23 | PHASE1 |
| NCT07448402 | Caja Costarricense de Seguro Social | Psoriasis|Psoriasis Arthritis|Psoriasis (PsO) | 2026-05 | |
| NCT03706040 | AbbVie | Dermatitis | 2018-12-27 | PHASE2 |
| NCT03875482 | AbbVie | Psoriasis | 2019-05-13 | PHASE3 |
| NCT03047395 | AbbVie | Psoriasis | 2017-02-27 | PHASE3 |
| NCT05283694 | AbbVie | Healthy Volunteers | 2017-09-11 | PHASE1 |
| NCT03105128 | AbbVie | Crohn´s Disease | 2017-05-10 | PHASE3 |
| NCT03518047 | AbbVie | Psoriasis | 2018-07-19 | PHASE3 |
| NCT07352566 | University of California, San Francisco | Psoriasis|Atopic Dermatitis | 2026-01-01 | PHASE4 |
| NCT02443298 | AbbVie|Boehringer Ingelheim | Asthma | 2015-06-23 | PHASE2 |
| NCT07499232 | Janssen Research & Development, LLC | Crohn Disease | 2026-04-21 | PHASE3 |
| NCT03000075 | AbbVie|Boehringer Ingelheim | Psoriasis | 2016-12-02 | PHASE2 |
| NCT06571266 | AbbVie | Healthy Volunteers | 2024-09-11 | PHASE1 |
| NCT03022045 | AbbVie | Psoriasis | 2017-01-26 | PHASE3 |
| NCT06333860 | AbbVie | Moderate Plaque Psoriasis | 2024-05-10 | PHASE4 |
| NCT07466550 | AbbVie | Healthy Volunteer | 2026-03-08 | PHASE1 |
| NCT07177118 | First Affiliated Hospital of Wenzhou Medical University|Taizhou Hospital|Second Affiliated Hospital of Wenzhou Medical University | Crohn Disease|Crohn Disease and Ulcerative Colitis | 2025-10-20 | PHASE3 |
| NCT06641089 | MoonLake Immunotherapeutics AG | Arthritis, Psoriatic | 2024-10-15 | PHASE3 |
| NCT03398148 | AbbVie | Ulcerative Colitis (UC) | 2018-03-07 | PHASE2|PHASE3 |
| NCT07138898 | NYU Langone Health | Rheumatic Disease | 2025-09 | PHASE2 |
| NCT04713592 | AbbVie | Psoriasis | 2021-02-26 | PHASE3 |
| NCT07007091 | AbbVie | Healthy Volunteers | 2025-06-12 | PHASE1 |
| NCT06880744 | AbbVie | Ulcerative Colitis | 2025-06-17 | PHASE3 |
| NCT05969223 | AbbVie | Genital Psoriasis|Scalp Psoriasis | 2023-08-10 | PHASE4 |
| NCT03914261 | AbbVie | Crohn´s Disease|Ulcerative Colitis (UC) | | |
| NCT05083078 | Janssen Research & Development, LLC | Arthritis, Psoriatic|Healthy | 2021-11-04 | PHASE1 |
| NCT04102007 | AbbVie | Plaque Psoriasis | 2019-11-12 | PHASE3 |
| NCT04524611 | AbbVie | Crohn´s Disease (CD) | 2020-09-30 | PHASE3 |
| NCT04340076 | Radboud University Medical Center|ZonMw: The Netherlands Organisation for Health Research and Development|Belgium Health Care Knowledge Centre|University Hospital, Ghent | Psoriasis|Psoriasis Vulgaris | 2020-08-20 | PHASE4 |
| NCT04451720 | AbbVie | Palmoplantar Pustulosis (PPP) | 2020-07-20 | PHASE3 |
| NCT04799990 | AbbVie | Psoriasis | 2021-06-23 | |
| NCT02513459 | AbbVie|Boehringer Ingelheim | Crohn Disease | 2015-09-16 | PHASE2 |
| NCT06937619 | AbbVie | Healthy Volunteer | 2025-04-21 | PHASE1 |
| NCT05274100 | AbbVie | Healthy Volunteers | 2020-09-01 | PHASE1 |
| NCT02684370 | AbbVie|Boehringer Ingelheim | Psoriasis | 2016-02 | PHASE3 |
| NCT05283135 | Oregon Medical Research Center|AbbVie | Psoriasis | 2022-03-01 | PHASE2 |
| NCT02203851 | AbbVie|Boehringer Ingelheim | Psoriasis | 2014-11-20 | PHASE2 |
| NCT04908475 | AbbVie | Psoriasis | 2021-06-09 | PHASE4 |
| NCT06100744 | AbbVie | Juvenile Psoriatic Arthritis | 2024-07-08 | PHASE3 |
| NCT02672852 | AbbVie|Boehringer Ingelheim | Psoriasis | 2016-02-29 | PHASE3 |
| NCT03675308 | AbbVie | Psoriatic Arthritis | 2019-03-25 | PHASE3 |
| NCT02694523 | AbbVie|Boehringer Ingelheim | Psoriasis | 2016-03 | PHASE3 |
| NCT03104413 | AbbVie | Crohn´s Disease | 2017-12-18 | PHASE3 |
| NCT03875508 | AbbVie | Psoriasis | 2019-06-04 | PHASE3 |
| NCT03398135 | AbbVie | Ulcerative Colitis (UC) | 2018-08-28 | PHASE3 |
| NCT02031276 | AbbVie|Boehringer Ingelheim | Crohn Disease | 2014-02 | PHASE2 |
| NCT04435600 | AbbVie | Psoriasis | 2020-07-14 | PHASE3 |
| NCT02986373 | AbbVie | Psoriatic Arthritis | 2016-12-15 | PHASE2 |
| NCT05268068 | AbbVie | Healthy Volunteers | 2019-06-27 | PHASE1 |
| NCT06054425 | AbbVie | Healthy Volunteers | 2023-11-20 | PHASE1 |
| NCT02047110 | AbbVie|Boehringer Ingelheim | Ankylosing Spondylitis (AS) | 2014-01-28 | PHASE2 |
| NCT03255382 | AbbVie | Psoriasis | 2017-08-22 | PHASE3 |
| NCT03105102 | AbbVie | Crohn´s Disease | 2018-04-09 | PHASE3 |
| NCT02719171 | AbbVie|Boehringer Ingelheim | Arthritis, Psoriatic | 2016-04 | PHASE2 |
| NCT05995353 | AbbVie | Crohn´s Disease | 2023-12-11 | PHASE3 |
| NCT04254783 | AbbVie | Ulcerative Colitis (UC)|Crohn´s Disease | 2020-05-27 | PHASE1 |
| NCT02054481 | Boehringer Ingelheim | Psoriasis | 2014-02 | PHASE2 |
| NCT01577550 | AbbVie|Boehringer Ingelheim | Psoriasis | 2012-04 | PHASE1 |
| NCT02596217 | AbbVie|Boehringer Ingelheim | Healthy | 2015-08 | PHASE1 |